# Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

> **NCT05303129** · NA · COMPLETED · sponsor: **Centre Francois Baclesse** · enrollment: 165 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** Blood sampling

## Key facts

- **NCT ID:** NCT05303129
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-27
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303129, "Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05303129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*